Entrada (TRDA) Q2 Revenue Drops 98%
Entrada Therapeutics (NASDAQ:TRDA), a biotechnology company developing intracellular therapies for rare neuromuscular diseases, reported second quarter 2025 financial results on August 6, 2025. The main news from the release was a sharp drop in revenue from collaboration activities and a larger-than-expected net loss per share, due in large part to the conclusion of major partnership milestones. The company reported a GAAP loss per share of $(1.04) in Q2 2025 versus the average analyst estimate of $(0.85), while GAAP revenue was $2.0 million, falling far short of the $9.65 million GAAP consensus estimate. Compared to the same quarter last year, GAAP revenue was down 97.9% year-over-year, and expenses—mainly for research and personnel—rose by about 18%. Leadership highlighted clinical and regulatory advancements, and maintained that its $354.0 million in cash, cash equivalents, and marketable securities as of June 30, 2025, will fund operations for at least two more years. The quarter marked execution of important pipeline milestones, but the financial results signal a challenging transition as Entrada moves toward developing its own products and away from partnership-driven revenue.
Source: Analyst estimates for the quarter provided by FactSet.
Entrada Therapeutics engineers and develops intracellular biologics, focusing on rare neuromuscular and genetic diseases. Its technology centers on the EEV Platform, which delivers drug molecules into cells—a key hurdle for therapies that target diseases within tissues such as muscle. The company’s pipeline includes Duchenne muscular dystrophy (DMD) therapies, programs for inherited retinal diseases, and rare metabolic conditions.
Source Fool.com
